Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesAmortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Verastem (VSTM) EBT: 2018-2025

Historic EBT for Verastem (VSTM) over the last 8 years, with Sep 2025 value amounting to -$39.9 million.

  • Verastem's EBT fell 6.71% to -$39.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$158.2 million, marking a year-over-year decrease of 52.40%. This contributed to the annual value of -$130.5 million for FY2024, which is 49.31% down from last year.
  • Verastem's EBT amounted to -$39.9 million in Q3 2025, which was up 7.65% from -$43.2 million recorded in Q2 2025.
  • In the past 5 years, Verastem's EBT ranged from a high of -$15.0 million in Q1 2021 and a low of -$43.4 million during Q1 2025.
  • Over the past 3 years, Verastem's median EBT value was -$29.8 million (recorded in 2024), while the average stood at -$30.1 million.
  • Within the past 5 years, the most significant YoY rise in Verastem's EBT was 60.43% (2021), while the steepest drop was 273.44% (2021).
  • Quarterly analysis of 5 years shows Verastem's EBT stood at -$16.5 million in 2021, then dropped by 1.94% to -$16.8 million in 2022, then fell by 11.49% to -$20.2 million in 2023, then plummeted by 84.97% to -$31.8 million in 2024, then fell by 6.71% to -$39.9 million in 2025.
  • Its last three reported values are -$39.9 million in Q3 2025, -$43.2 million for Q2 2025, and -$43.4 million during Q1 2025.